KURA
Price
$10.39
Change
+$0.96 (+10.18%)
Updated
Oct 8, 12:37 PM (EDT)
Capitalization
818.5M
22 days until earnings call
REPL
Price
$4.76
Change
+$0.11 (+2.37%)
Updated
Oct 8, 12:46 PM (EDT)
Capitalization
362.96M
41 days until earnings call
Interact to see
Advertisement

KURA vs REPL

Header iconKURA vs REPL Comparison
Open Charts KURA vs REPLBanner chart's image
Kura Oncology
Price$10.39
Change+$0.96 (+10.18%)
Volume$4.19K
Capitalization818.5M
Replimune Group
Price$4.76
Change+$0.11 (+2.37%)
Volume$100
Capitalization362.96M
KURA vs REPL Comparison Chart in %
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KURA vs. REPL commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and REPL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (KURA: $9.43 vs. REPL: $4.65)
Brand notoriety: KURA and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 83% vs. REPL: 56%
Market capitalization -- KURA: $818.5M vs. REPL: $362.96M
KURA [@Biotechnology] is valued at $818.5M. REPL’s [@Biotechnology] market capitalization is $362.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, KURA is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 6 bullish TA indicator(s).

  • KURA’s TA Score: 5 bullish, 4 bearish.
  • REPL’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, REPL is a better buy in the short-term than KURA.

Price Growth

KURA (@Biotechnology) experienced а +6.55% price change this week, while REPL (@Biotechnology) price change was +10.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.29%. For the same industry, the average monthly price growth was +18.13%, and the average quarterly price growth was +86.40%.

Reported Earning Dates

KURA is expected to report earnings on Oct 30, 2025.

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+8.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KURA($818M) has a higher market cap than REPL($363M). KURA YTD gains are higher at: 8.266 vs. REPL (-61.602). KURA has higher annual earnings (EBITDA): -192.46M vs. REPL (-268.18M). KURA has more cash in the bank: 631M vs. REPL (403M). KURA has less debt than REPL: KURA (19.5M) vs REPL (76.3M). KURA has higher revenues than REPL: KURA (83.3M) vs REPL (0).
KURAREPLKURA / REPL
Capitalization818M363M225%
EBITDA-192.46M-268.18M72%
Gain YTD8.266-61.602-13%
P/E RatioN/AN/A-
Revenue83.3M0-
Total Cash631M403M157%
Total Debt19.5M76.3M26%
FUNDAMENTALS RATINGS
KURA vs REPL: Fundamental Ratings
KURA
REPL
OUTLOOK RATING
1..100
726
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4095
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (13) in the Biotechnology industry is in the same range as KURA (26). This means that REPL’s stock grew similarly to KURA’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KURA (100). This means that REPL’s stock grew similarly to KURA’s over the last 12 months.

KURA's SMR Rating (97) in the Biotechnology industry is in the same range as REPL (98). This means that KURA’s stock grew similarly to REPL’s over the last 12 months.

KURA's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for REPL (95). This means that KURA’s stock grew somewhat faster than REPL’s over the last 12 months.

KURA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as REPL (100). This means that KURA’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURAREPL
RSI
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SFES0.900.03
+2.95%
Safeguard Scientifics, Inc.
DBSDF44.561.02
+2.34%
DBS Group Holdings Ltd.
OZFRY2.65N/A
N/A
OFX Group Limited
KIKOF8.44N/A
N/A
Kikkoman Corp.
RYHTY7.11N/A
N/A
Ryman Healthcare Ltd.

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with PYXS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
-3.78%
PYXS - KURA
61%
Loosely correlated
+3.24%
KYMR - KURA
43%
Loosely correlated
-1.09%
XNCR - KURA
42%
Loosely correlated
+2.04%
ZYME - KURA
42%
Loosely correlated
-1.11%
REPL - KURA
41%
Loosely correlated
-0.64%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with NEVPF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-0.64%
NEVPF - REPL
64%
Loosely correlated
N/A
ELVAF - REPL
60%
Loosely correlated
+27.78%
IMNN - REPL
57%
Loosely correlated
+1.91%
SNDX - REPL
49%
Loosely correlated
+0.30%
KYMR - REPL
45%
Loosely correlated
-1.09%
More